Control Shunt Infections
Implanting a shunt system, which includes a valve and catheter, is the most common treatment for hydrocephalus.1 However, shunt infections are a serious complication, affecting 7-15% of patients.2 This complication affects pediatric as well as adult patients and impairs their quality of life, cognitive function and shunt survival.3 Using antibiotic-impregnated catheters can prevent up to two-thirds of these infections.2
Extra protection against infection
The XABO Antibiotic-Impregnated Catheters are treated with antimicrobial agents during production, allowing them to release antibiotics into the surrounding tissue after implantation.
Extended shelf life for up to 36 months
- The only catheters for hydrocephalus therapy with a shelf life of up to 36 months.4
- Can withstand temperatures up to 86°F (30°C) without losing effectiveness.4
38-day continuous antibiotic release after implantation
- Optimized release kinetics ensure continuous antibiotic release for at least 38 days post-implantation.4
- Provides antimicrobial activity during the critical period when patients are most susceptible to infection.5-8
- High potency of clindamycin hydrochloride and rifampicin allows for low-dose antibiotic release, which may help minimize allergic reactions and reduce the risk of resistance development.
Contact us
Please complete the form below and an Aesculap representative will contact you.
Contact us
Please complete the form below and an Aesculap representative will contact you.
Your request could not be submitted. Please try again.
warningReferences (See brochure references):
1Hydrocephalus Association. (2021). What is Hydrocephalus? | Hydrocephalus Association. www.hydroassoc.org. https://www.hydroassoc.org/about-hydrocephalus/
2Fernández-Méndez R, Richards HK, Seeley HM, et al. Current epidemiology of cerebrospinal fluid shunt surgery in the UK and Ireland (2004-2013).
3Vinchon M, Dhellemmes P. Cerebrospinal fluid shunt infection: risk factors and long-term follow-up. Childs Nerv Syst 2006;22(7):692–97.
4MIETHKE report. Data on file.
5Okamura Y, Maruyama K, Fukuda S, et al. Detailed standardized protocol to prevent cerebrospinal fluid shunt infection. J Neurosurg 2019:1–5.
6Borgbjerg BM, Gjerris F, Albeck MJ, Børgesen SE. Risk of infection after cerebrospinal fluid shunt: an analysis of 884 first-time shunts. Acta Neurochir (Wien). 1995;136(1-2):1-7.
7George R, Leibrock L, Epstein M. Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience. J Neurosurg. 1979;51(6):804-811.
8Wells DL, Allen JM. Ventriculoperitoneal shunt infections in adult patients. AACN Adv Crit Care. 2013;24(1):6-14.